Literature DB >> 26317331

6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.

Lei Wang1, Adrianne Wallace2, Sudhir Raghavan1, Siobhan M Deis3, Mike R Wilson4, Si Yang1, Lisa Polin2,4, Kathryn White2,4, Juiwanna Kushner2,4, Steven Orr2, Christina George2, Carrie O'Connor2, Zhanjun Hou2,4, Shermaine Mitchell-Ryan4, Charles E Dann3, Larry H Matherly2,4,5, Aleem Gangjee1.   

Abstract

2-Amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine antifolate thiophene regioisomers of AGF94 (4) with a thienoyl side chain and three-carbon bridge lengths [AGF150 (5) and AGF154 (7)] were synthesized as potential antitumor agents. These analogues inhibited proliferation of Chinese hamster ovary (CHO) sublines expressing folate receptors (FRs) α or β (IC50s < 1 nM) or the proton-coupled folate transporter (PCFT) (IC50 < 7 nM). Compounds 5 and 7 inhibited KB, IGROV1, and SKOV3 human tumor cells at subnanomolar concentrations, reflecting both FRα and PCFT uptake. AGF152 (6) and AGF163 (8), 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine thiophene regioisomers, also inhibited growth of FR-expressing CHO and KB cells. All four analogues inhibited glycinamide ribonucleotide formyltransferase (GARFTase). Crystal structures of human GARFTase complexed with 5 and 7 were reported. In severe combined immunodeficient mice bearing SKOV3 tumors, 7 was efficacious. The selectivity of these compounds for PCFT and for FRα and β over the ubiquitously expressed reduced folate carrier is a paradigm for selective tumor targeting.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26317331      PMCID: PMC4714714          DOI: 10.1021/acs.jmedchem.5b00801

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  59 in total

Review 1.  Dysregulated pH: a perfect storm for cancer progression.

Authors:  Bradley A Webb; Michael Chimenti; Matthew P Jacobson; Diane L Barber
Journal:  Nat Rev Cancer       Date:  2011-08-11       Impact factor: 60.716

2.  Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.

Authors:  Yiqiang Wang; Christina Cherian; Steven Orr; Shermaine Mitchell-Ryan; Zhanjun Hou; Sudhir Raghavan; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2013-10-30       Impact factor: 7.446

3.  The human glycinamide ribonucleotide transformylase domain: purification, characterization, and kinetic mechanism.

Authors:  C A Caperelli; E L Giroux
Journal:  Arch Biochem Biophys       Date:  1997-05-01       Impact factor: 4.013

Review 4.  The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.

Authors:  Larry H Matherly; Mike R Wilson; Zhanjun Hou
Journal:  Drug Metab Dispos       Date:  2014-01-06       Impact factor: 3.922

5.  Long-term folate deficiency alters folate content and distribution differentially in rat tissues.

Authors:  G Varela-Moreiras; J Selhub
Journal:  J Nutr       Date:  1992-04       Impact factor: 4.798

Review 6.  The folate receptor: what does it promise in tissue-targeted therapeutics?

Authors:  Marcela D'Alincourt Salazar; Manohar Ratnam
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

7.  (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.

Authors:  G Pizzorno; B A Moroson; A R Cashmore; G P Beardsley
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

8.  Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.

Authors:  Sita Kugel Desmoulin; Lei Wang; Lisa Polin; Kathryn White; Juiwanna Kushner; Mark Stout; Zhanjun Hou; Christina Cherian; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2012-06-26       Impact factor: 4.436

9.  Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.

Authors:  Martin H Cohen; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2009-09-08

10.  Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard.

Authors:  Thomas C Terwilliger; Ralf W Grosse-Kunstleve; Pavel V Afonine; Nigel W Moriarty; Peter H Zwart; Li Wei Hung; Randy J Read; Paul D Adams
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-12-05
View more
  18 in total

1.  Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.

Authors:  Manasa Ravindra; Mike R Wilson; Nian Tong; Carrie O'Connor; Mohammad Karim; Lisa Polin; Adrianne Wallace-Povirk; Kathryn White; Juiwanna Kushner; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2018-04-27       Impact factor: 7.446

2.  Cellular Pharmacodynamics of a Novel Pyrrolo[3,2-d]pyrimidine Inhibitor Targeting Mitochondrial and Cytosolic One-Carbon Metabolism.

Authors:  Aamod S Dekhne; Changwen Ning; Md Junayed Nayeen; Khushbu Shah; Hasini Kalpage; Josephine Frühauf; Adrianne Wallace-Povirk; Carrie O'Connor; Zhanjun Hou; Seongho Kim; Maik Hüttemann; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2019-11-09       Impact factor: 4.436

3.  Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.

Authors:  Manasa Ravindra; Adrianne Wallace-Povirk; Mohammad A Karim; Mike R Wilson; Carrie O'Connor; Kathryn White; Juiwanna Kushner; Lisa Polin; Christina George; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2018-02-21       Impact factor: 7.446

Review 4.  The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.

Authors:  Larry H Matherly; Zhanjun Hou; Aleem Gangjee
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-10       Impact factor: 3.333

5.  Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.

Authors:  Lalit K Golani; Farhana Islam; Carrie O'Connor; Aamod S Dekhne; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2020-05-06       Impact factor: 3.641

6.  Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy.

Authors:  Aamod S Dekhne; Khushbu Shah; Gregory S Ducker; Jade M Katinas; Jennifer Wong-Roushar; Md Junayed Nayeen; Arpit Doshi; Changwen Ning; Xun Bao; Josephine Frühauf; Jenney Liu; Adrianne Wallace-Povirk; Carrie O'Connor; Sijana H Dzinic; Kathryn White; Juiwanna Kushner; Seongho Kim; Maik Hüttemann; Lisa Polin; Joshua D Rabinowitz; Jing Li; Zhanjun Hou; Charles E Dann; Aleem Gangjee; Larry H Matherly
Journal:  Mol Cancer Ther       Date:  2019-07-09       Impact factor: 6.261

7.  Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates.

Authors:  Zhanjun Hou; Leda Gattoc; Carrie O'Connor; Si Yang; Adrianne Wallace-Povirk; Christina George; Steve Orr; Lisa Polin; Kathryn White; Juiwanna Kushner; Robert T Morris; Aleem Gangjee; Larry H Matherly
Journal:  Mol Cancer Ther       Date:  2017-01-30       Impact factor: 6.261

8.  Development and validation of chemical features-based proton-coupled folate transporter/activity and reduced folate carrier/activity models (pharmacophores).

Authors:  Khushbu Shah; Sudhir Raghavan; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Mol Graph Model       Date:  2018-02-20       Impact factor: 2.518

9.  Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.

Authors:  Lalit K Golani; Adrianne Wallace-Povirk; Siobhan M Deis; Jennifer Wong; Jiyuan Ke; Xin Gu; Sudhir Raghavan; Mike R Wilson; Xinxin Li; Lisa Polin; Parker W de Waal; Kathryn White; Juiwanna Kushner; Carrie O'Connor; Zhanjun Hou; H Eric Xu; Karsten Melcher; Charles E Dann; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2016-08-26       Impact factor: 7.446

10.  Functional and mechanistic roles of the human proton-coupled folate transporter transmembrane domain 6-7 linker.

Authors:  Mike R Wilson; Zhanjun Hou; Lucas J Wilson; Jun Ye; Larry H Matherly
Journal:  Biochem J       Date:  2016-08-11       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.